Alpha TeknovaTKNO
About: Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
Employees: 173
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
333% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 6
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
18% more capital invested
Capital invested by funds: $31.7M [Q1] → $37.5M (+$5.77M) [Q2]
3% more funds holding
Funds holding: 64 [Q1] → 66 (+2) [Q2]
2.85% more ownership
Funds ownership: 11.45% [Q1] → 14.3% (+2.85%) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TKNO.
Financial journalist opinion
Based on 3 articles about TKNO published over the past 30 days









